From Casetext: Smarter Legal Research

In re BioMarin Pharm., Inc. Sec. Litig.

United States District Court, Northern District of California
Sep 8, 2021
3:20-cv-06719-WHO (N.D. Cal. Sep. 8, 2021)

Opinion

3:20-cv-06719-WHO

09-08-2021

In re BioMarin Pharmaceutical Inc. Securities Litigation

COOLEY LLP JOHN C. DWYER (136533) (dwyerjc@cooley.com) JESSICA VALENZUELA SANTAMARIA (220934) (jvs@cooley.com) ALEX KASNER (310637) Attorneys for Defendants BioMarin Pharmaceutical Inc., Jean-Jacques Bienaimé, Brian R. Mueller, and Henry J. Fuchs COOLEY LLP Jessica Valenzuela Santamaria (220934) John C. Dwyer (136533) Alex Kasner (310637) Attorneys for Defendants BioMarin Pharmaceutical Inc., Jean-Jacques Bienaime, Brian R. Mueller, and Henry J. Fuchs BERNSTEIN LITOWITZ BERGER & GROSSMANN LLP Katherine M. Sinderson Salvatore Graziano (admitted pro hac vice) (salvatore@blbglaw.com) Jeroen Van Kwawegan (admitted pro hac vice) (jeroen@blbglaw.com) Katherine M. Sinderson (admitted pro hac vice) (katiem@blbglaw.com) Abe Alexander (admitted pro hac vice) (abe .alexander@blbglaw.com) Christopher R. Miles (admitted pro hac vice) (christopher.miles@blbglaw.com) Thomas Z. Serpber (pro hac vice motion pending) (thomas.sperber@blbglaw.com) Jonathan D. Uslaner (256898) (jonathanu@blbglaw.com) Lead Counsel for Lead Plaintiff and the Class


COOLEY LLP JOHN C. DWYER (136533) (dwyerjc@cooley.com) JESSICA VALENZUELA SANTAMARIA (220934) (jvs@cooley.com) ALEX KASNER (310637) Attorneys for Defendants BioMarin Pharmaceutical Inc., Jean-Jacques Bienaimé, Brian R. Mueller, and Henry J. Fuchs

COOLEY LLP Jessica Valenzuela Santamaria (220934) John C. Dwyer (136533) Alex Kasner (310637) Attorneys for Defendants BioMarin Pharmaceutical Inc., Jean-Jacques Bienaime, Brian R. Mueller, and Henry J. Fuchs

BERNSTEIN LITOWITZ BERGER & GROSSMANN LLP Katherine M. Sinderson

Salvatore Graziano (admitted pro hac vice) (salvatore@blbglaw.com)

Jeroen Van Kwawegan (admitted pro hac vice) (jeroen@blbglaw.com)

Katherine M. Sinderson (admitted pro hac vice) (katiem@blbglaw.com)

Abe Alexander (admitted pro hac vice) (abe .alexander@blbglaw.com)

Christopher R. Miles (admitted pro hac vice) (christopher.miles@blbglaw.com)

Thomas Z. Serpber (pro hac vice motion pending) (thomas.sperber@blbglaw.com)

Jonathan D. Uslaner (256898) (jonathanu@blbglaw.com)

Lead Counsel for Lead Plaintiff and the Class

WILLIAM H. ORRICK, UNITED STATES DISTRICT JUDGE

STIPULATION AND [PROPOSED[ ORDER TO RESCHEDULE MOTION TO DISMISS HEARING

Lead Plaintiff Arbejdsmarkedets Tillægspension (“ATP” or “Lead Plaintiff”) and Defendants BioMarin Pharmaceutical Inc., Jean-Jacques Bienaimé, Brian R. Mueller, and Henry J. Fuchs (“Defendants”) (collectively with ATP, the “Parties”) stipulate and agree as follows:

WHEREAS, on December 22, 2020, the Court issued an order appointing ATP Lead Plaintiff in the above-referenced action pursuant to the Private Securities Litigation Reform Act of 1995;

WHEREAS, on February 22, 2021, Lead Plaintiff filed an Amended Class Action Complaint;

WHEREAS, on April 22, 2021, Defendants filed a Motion to Dismiss Plaintiff's Amended Class Action Complaint and a Motion Hearing was set for September 8, 2021 at 2:00 p.m.;

WHEREAS, on June 22, 2021, Lead Plaintiff filed an Opposition to Defendants' Motion to Dismiss the Amended Class Action Complaint; Stipulation and [Proposed[ Order to Reschedule Motion to Dismiss

WHEREAS, on July 22, 2021, Defendants filed a Reply in Support of the Motion to Dismiss Plaintiff's Amended Class Action Complaint;

WHEREAS, on August 30, 2021, the Court entered a Clerk's Notice (“Order”) resetting the September 8, 2021 Motion Hearing to September 15, 2021 at 2:00 p.m.;

WHEREAS, counsel for Defendants have a professional conflict and will be unavailable for the rescheduled Motion Hearing;

WHEREAS, counsel for Defendants have another matter that is set for trial in the Northern District of California and will be unavailable for the duration of the trial;

WHEREAS, counsel for Defendants and for Lead Plaintiff have met and conferred and, at the request of counsel for Defendant and without objection from counsel for Lead Plaintiff, agreed to seek a continuance of the Motion Hearing from September 15, 2021 to November 17, 2021 at 2:00 p.m. or another date that is convenient for the Court.

NOW THEREFORE, the Parties, by and through their undersigned counsel, agree and stipulate to the following, subject to the Court's approval:

1. The Motion Hearing scheduled for September 15, 2021 at 2:00 p.m. shall be rescheduled to November 17, 2021 at 2:00 p.m.

IT IS SO STIPULATED.

ORDER

IT IS SO ORDERED.

ATTESTATION PURSUANT TO CIV. L.R. 5-1(I)(3)

Pursuant to Civil Local Rule 5-1(i)(3), I attest that concurrence in the filing of this document has been obtained from the other signatories.


Summaries of

In re BioMarin Pharm., Inc. Sec. Litig.

United States District Court, Northern District of California
Sep 8, 2021
3:20-cv-06719-WHO (N.D. Cal. Sep. 8, 2021)
Case details for

In re BioMarin Pharm., Inc. Sec. Litig.

Case Details

Full title:In re BioMarin Pharmaceutical Inc. Securities Litigation

Court:United States District Court, Northern District of California

Date published: Sep 8, 2021

Citations

3:20-cv-06719-WHO (N.D. Cal. Sep. 8, 2021)